LAG3 and melanoma: LAG-3 is known to inhibit APC activation, and in melanoma, MHCII expression was correlated with apoptotic resistance, possibly via LAG-3 engagement suggesting that anti-LAG-3 could be an important therapeutic strategy in MHC II expressing tumors [52, 53].